Screener
Aurinia Pharmaceuticals AUPH EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Aurinia Pharmaceuticals’s reported figures.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's EBITDA?
- Aurinia Pharmaceuticals (AUPH) reported EBITDA of $51.18M in Q2 2026.
- How has Aurinia Pharmaceuticals's EBITDA changed year-over-year?
- Aurinia Pharmaceuticals's EBITDA increased by 105.1% year-over-year, from $24.95M to $51.18M.
- What is the long-term trend for Aurinia Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's EBITDA has grown at a -8.6% compound annual growth rate (CAGR), from -$177.97M to $124.36M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Aurinia Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude